Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Eledon Pharmaceuticals Inc
ELDN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$2.24
-0.06
-2.61%
Últ. Act.: Oct 23, 12:16 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Eledon Pharmaceuticals Financials
Eledon Pharmaceuticals (ELDN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Eledon Pharma Q2 EPS $(0.27) Misses $(0.16) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.16) by 68.75 percent. This is a 107.69 percent decrease over losses of $(0.13) per share from
Benzinga Newsdesk
PRO
Eledon Pharma Q1 EPS $(0.33) Misses $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.18) by 83.33 percent. This is a 312.5 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.
Vandana Singh
PRO
Eledon Pharma Q4 EPS $(0.10) Beats $(0.18) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.18) by 45.95 percent. This is a 84.38 percent increase over losses of $(0.64) per share from the
Benzinga Newsdesk
PRO
Eledon Pharma Q3 EPS $(0.21) Beats $(0.24) Estimate
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.24) by 11.39 percent. This is a 25 percent increase over losses of $(0.28) per share from the
Benzinga Newsdesk
Dow Dips Over 200 Points; Fluor Shares Slide After Q3 Results
Avi Kapoor
